Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 21Endocrine 21Thoracic 2Sarcoma 2NET 2Gastrointestinal 2CNS 2Plasma cell 1Other hematologic neoplasm 1Dermatologic 1Breast 1

Conditions

Leukemia, Myeloid, Acute 772Leukemia 596Leukemia, Lymphocytic, Chronic, B-Cell 535Precursor Cell Lymphoblastic Leukemia-Lymphoma 485Myelodysplastic Syndromes 408Lymphoma, Non-Hodgkin 265Lymphoma 265Hematologic Neoplasms 251Leukemia, Myelogenous, Chronic, BCR-ABL Positive 232Multiple Myeloma 199Hodgkin Disease 193Lymphoma, Follicular 181Lymphoma, Mantle-Cell 179Lymphoma, B-Cell, Marginal Zone 156Lymphoma, Large B-Cell, Diffuse 155Burkitt Lymphoma 155Recurrence 149Leukemia, Myelomonocytic, Chronic 139Congenital Abnormalities 131Myeloproliferative Disorders 122Waldenstrom Macroglobulinemia 106Neoplasms 97Leukemia, Myeloid, Chronic-Phase 97Lymphoma, Large-Cell, Immunoblastic 91Primary Myelofibrosis 88Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 81Blast Crisis 80Leukemia, Myeloid, Accelerated Phase 74Anemia, Refractory, with Excess of Blasts 72Lymphoma, T-Cell, Cutaneous 68

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thyroid Carcinoma, Anaplastic × Other hematologic neoplasm × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡